- Mr. Greg McKee, CEO of Tryp Therapeutics, appeared on The Dealmaker Podcast to share insights on the company and the psychedelics industry
- During the interview, he discussed the potential of psychedelics in the treatment of PTSD and other mental disorders
- Greg also shared the challenges that the industry is facing currently, mostly to do with legislation
- McKee also shared how people can help the company and the industry by pushing for the decriminalization of psychedelics and taking part in clinical trials
On August 2, 2021, the Dealmaker Podcast posted an interview with Greg McKee, the Chief Executive Officer (“CEO”) of Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF). The show, hosted by Oren Klaff, sought to give the audience an understanding of Tryp Therapeutics’ operations, along with Mr. McKee’s personal story on how he ended up as the CEO of the company (https://ibn.fm/Puuse). It offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level.
When discussing what Tryp Therapeutics is all about, Mr. McKee acknowledged the current boom in the psychedelics space and the potential that these substances hold. He noted:
“There are a lot of naturally-derived chemistries around that eventually find their way into more traditional drug development pathways. Psychedelics are some of those.”
Mr. McKee mentioned his interaction with former Navy SEALs, all of whom developed Post-Traumatic Stress Disorder (“PTSD”), along with other mental disorders. The patients did not see lasting efficacy on their current and standard of care treatments. Their use of more mainstream forms of therapy and treatment did not seem to work until they tried 5-MeO-DMT, a psychedelic. However, these patients did see an impact after using a psychedelic compound.
The success of this psychedelic to these former Navy SEALs gave McKee the reassurance he needed that psychedelics could be of help, not just to former military officers but also to millions of other patients who suffer from chronic pain. However, he noted the most important hindrance along the way, approval.
“If we can bring these chemistries to market through an FDA pathway, then we think we can completely change those patients’ lives, along with many, many other kinds of patients that suffer from chronic pain,” he noted (https://ibn.fm/pncrO).
Tryp Therapeutics is a pharmaceutical company that develops clinical-stage compounds designed to treat diseases with high unmet medical needs. It seeks to achieve this through accelerated regulatory pathways. The company’s current flagship program involves developing synthetic psilocybin drug candidates to treat chronic pain and eating disorder indications. It regards itself as a pioneer in developing psilocybin-related drugs and hopes to follow the same path as some cannabis pioneers that have made waves and achieved a lot in the past couple of years.
The interview showed Mr. McKee’s passion for the job and how much he aligns with his company’s vision. He pointed out that although he is not the founder of the company, he understood the vision that the founder had for the company and the commitment it takes to be the company’s CEO.
More importantly, Mr. McKee cited the benefits that come with the use of psilocybin in treating pain. For one, he discussed their effectiveness without the accompanying risk of addiction associated with opioids. He also acknowledged that psychedelics are far from mainstream, but that is an opportunity for the company to play the role of a first-mover.
“They (psychedelics) are not mainstream yet. That’s actually the opportunity. Nobody’s done that yet. We’re just now making them synthetically and making them up to pharmaceutical-grade standards,” Mr. McKee noted.
McKee noted that FDA approvals take time. However, he pointed out that if anyone wanted to play a role in the industry’s growth and, more specifically, the development of Tryp Therapeutics, they could write to or call their legislators to push for the decriminalization of psychedelics. He also noted that the company welcomes people with any diseases it addresses to participate in their clinical study.
This interview offered a glimpse into Tryp Therapeutics operations, the opportunities and challenges within the psychedelics industry. Additionally, it provided insights into Mr. McKee’s ambitions, his vision for the company, along with his informed opinion on the psychedelics industry that is currently experiencing a spike in growth.
To listen to the whole podcast episode, please visit https://ibn.fm/avEnz
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.